The Future of Plasma – Subcutaneous and Recombinant Tech
The plasma industry is currently undergoing a shift toward more patient-friendly delivery systems and "synthetic" alternatives.
Innovations in Delivery
Subcutaneous Immunoglobulin (SCIg): Allows patients to self-administer their antibody therapy at home using a small needle under the skin, rather than spending hours in a hospital for an IV infusion.
Recombinant Factors: Scientists can now grow certain clotting factors in lab-grown cells without using human plasma at all. While this reduces the reliance on donors, plasma-derived products remain essential for many patients who develop "inhibitors" (antibodies) to synthetic versions.
1 View